key: cord-0881983-dxetldep
authors: Baghaei, Parvaneh; Dastan, Farzaneh; Marjani, Majid; Moniri, Afshin; Abtahian, Zahra; Ghadimi, Somayeh; Valizadeh, Melika; Heshmatnia, Jalal; Sadat Mirenayat, Maryam; Abedini, Atefeh; Kiani, Arda; Eslaminejad, Alireza; Mohammad Reza Hashemian, Seyed; Jamaati, Hamidreza; Zali, Alireza; Akbar Velayati, Ali; Tabarsi, Payam
title: Combination therapy of IFNβ1 with lopinavir–ritonavir, increases oxygenation, survival and discharging of sever COVID-19 infected inpatients
date: 2020-12-26
journal: Int Immunopharmacol
DOI: 10.1016/j.intimp.2020.107329
sha: e5a68d0227c874c5caa474b74ee348c92856ba50
doc_id: 881983
cord_uid: dxetldep

Interferon Beta-1a (IFN-β1-a), an immunomodulatory mediator with antiviral effects, has shown in vivo and in vitro activities especially on coronavirus including SARS-CoV-2. COVID-19 defined as the disease caused by infection with SARS-CoV-2. The virus has been illustrated inhibits the production of IFN-β1-a from inflammatory cells. We conducted a retrospective study of all adult confirmed COVID-19 hospitalized patients who received combination of three doses of 12 million international units of IFN-β1-a and Lopinavir 400mg and Ritonavir 100 mg every 12 h (case group) for 14 days besides standard care and age- and sex- matched COVID-19 patients with receiving lopinavir/ritonavir (control group) at Masih Daneshvari Hospital as a designated hospital for COVID-19 between Feb 19 and Apr 30, 2020. Multivariate analysis was done to determine the impact of IFN-β1-a on outcome and all-cause mortality. 152 cases in IFN-β1-a group and 304 cases as control group were included. IFN-β1-a group stayed at hospital longer and required noninvasive ventilation more than control group (13 vs. 6 days, p=0.001) and (34% vs. 24%, p=0.04), respectively. During treatment, 57 (12.5%) patients died. The death rate in case and control groups was 11% and 13% respectively. In multivariate analysis, not receiving IFN-β1-a (HR 5.12, 95% CI: 2.77- 9.45), comorbidity (HR 2.28, 95% CI: 1.13- 4.60) and noninvasive ventilation (HR 2.77, 95% CI: 1.56- 4.93) remained significantly associated with all-cause mortality. In this study, risk of death decreased by using IFN-β1-a in COVID-19 patients. More clinical study will be necessary to measure efficacy of IFN-β1-a in COVID-19 treatment.

Interferon Beta-1a (IFN-1-a), an immunomodulatory mediator with antiviral effects, has shown in vivo and in vitro activities especially on coronavirus including SARS-CoV-2.

COVID-19 defined as the disease caused by infection with SARS-CoV-2. The virus has been illustrated inhibits the production of IFN-1-a from inflammatory cells. We conducted a retrospective study of all adult confirmed COVID-19 hospitalized patients who received combination of three doses of 12 million international units of IFN-1-a and Lopinavir 400mg and Ritonavir 100 mg every 12 h (case group) for 14 days besides standard care and age-and sex-matched COVID-19 patients with receiving lopinavir/ritonavir (control group) at Masih Daneshvari Hospital as a designated hospital for COVID -19 between Feb 19 and Apr 30, 2020 . Multivariate analysis was done to determine the impact of IFN-1-a on outcome and all-cause mortality. 152 cases in IFN-1-a group and 304 cases as control group were included. IFN-1-a group stayed at hospital longer and required noninvasive ventilation more than control group (13 vs. 6 days, p=0.001) and (34% vs. 24%, p=0.04), respectively. During treatment, 57 (12.5%) patients died. The death rate in case and control groups was 11% and 13% respectively. In multivariate analysis, not receiving IFN-1-a (HR 5.12, 95% CI: 2.77-9.45), comorbidity (HR 2.28, ) and noninvasive ventilation (HR 2.77, ) remained significantly associated with all-cause mortality. In this study, risk of death decreased by using IFN-1-a in COVID-19 patients. More clinical study will be necessary to measure efficacy of IFN-1-a in COVID-19 treatment.

Keywords: Covid-19, IFN-1-a, survival, intensive care, outcome, mortality

COVID-19, the infection caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become an overwhelming and worldwide dilemma of health care system since Dec 2019. [1, 2] The virus transmitted promptly by person to person and has various symptoms from asymptomatic to respiratory failure and eventually death. [3] [4] [5] In addition, it has shown cytokine storm by increasing uncontrolled cytokines such as interleukin 6 (IL-6) in some cases however; there is no specific treatment or antiviral agents to suppress virus and consequent inflammation. [6] Antiviral defense especially interferon (IFN) release system can be inhibited by viruses such as SARS and Middle East respiratory syndrome coronavirus (MERS-CoV). [7] On the other hand, type I IFN may reduce as a consequence of a generalized immunosuppression induced by high viral load. [8] It is shown that IFNs' circulation is not detectable in infected patients such as COVID-19. [9] Moreover, severe and critical patients displayed lower activity and diminished response of type ɪ IFN compared to mild to moderate patients. [9] Thus usage IFN can be effective in antiviral immunity. Among IFNs, type I IFN particularly IFN was utilized for treatment coronavirus in different studies and had various results.

In general IFN is a more powerful inhibitor of coronavirus than IFNα. [10, 11] At present, few clinical trials suggest usage IFN on treatment and controlling COVID-19 in the world. [12] Current treatment includes oxygen support, antibiotics, some unproved antiviral drugs, anti-inflammatory compounds and immunoglobulin. Lopinavir and ritonavir and interferon beta (IFN-) have been shown to have efficient activity on serious adverse events (respiratory failure or death) of SARS and MERS-CoV [13, 14] and have improved pulmonary function. [15] Iran has got involved in COVID-19 extensively in Middle East Region in Asia. [16] As many countries, COVID-19 was a new storm for clinicians in Iran however we had an experience with H1N1. [17] Finding efficient medication with considering previous experience is a moral duty of clinicians and researchers. In this report, we illustrated outcomes in a nested case-control study of patients admitted for COVID-19 with or without using IFN-1-a in a referral center in Tehran, Iran. 

We included all adult confirmed COVID-19 patients who received three to five doses of IFN-1-a (ReciGen®, CinnaGen, Iran) 12 million international units (44µg) subcutaneous injection on alternate days (during five days) at the beginning of admission at hospital and lopinavir 400 mg plus ritonavir 100 mg twice a day for 14 days with standard careas cases. [19] The cases were received IFN-1-a if they were adult (age≥18 years), had a positive RT-PCR of the throat swab for COVID-19, and severe disease. Respiratory rate≥30 breaths/min or an oxygen saturation (Sao 2 )≤ 90%in room air or a partial pressure of arterial oxygen to percentage of inspired oxygen ratio (PaO2/FiO2) of ≤ 300 was considered as a severe disease. We excluded the patients with a history of allergy to IFN, other causes of lower respiratory infection such as viruses, bacteria, fungal and receiving less than three doses of IFN. We randomly selected in a 1:2ratio age-and sex-matched control with lopinavir and ritonavir regimen without using any type of IFN. Supportive treatment such as antipyretic, antibiotics, serum therapy and supplemental oxygen by nasal or mask as needed on clinician's discretion is provided. For both cases and controls, all patients had a diagnostic positive RT-PCR for COVID-19 with a chest imaging compatible to coronavirus infection and had a Sao 2 92% or less while breathing ambient air. In addition, we adjusted dose of lopinavir plus ritonavir in the cases who had treatmentemergent increase in serum ALT greater than five times the upper limit of normal. All cases or their legally authorized representative must have signed informed consent form.

All patients could be discharged if they had a negative RT-PCR, a Sao 2 ≥ 93% in ambient air for 15 minutes, and no fever for in last 24 hours.

We abstracted demographic and clinical information from patient records. The primary study outcomes were improvement of oxygen requirement, survival, and all-cause mortality. We defined improvement as a Sao 2 more than 93% while breathing ambient air in sitting position. When the patients were in improvement situation, we discharged them with health care recommendation such as wearing mask, hand hygiene frequently, at least two meter distance of other people and improving airflow at home.

We compared categorical variables using the chi-squared or Fisher's exact test and non-normally distributed continuous variables using the Mann Whitney U test. Multivariate logistic regression adjusting for age and gender was done to determine whether using IFN-1-a was independently associated with survival or improvement of oxygen requirement. Other predictors in the model entered if they were associated with survival or improvement of oxygen support and IFN-1-a in bivariate analysis at p<0.2. Kaplan-Meier survival analysis was used to examine the relationship between IFN-1-a and treatment outcome (all-cause mortality) and survival curves using log-rank test were compared during days at hospital. Additionally, we performed Cox proportional hazards modeling adjusting for age and gender to determine whether not using IFN-1-a was an independent risk factor for mortality and developing to invasive ventilation. Diabetes and other comorbidities are known to impact outcomes therefore they were considered as predictors. [20, 21] These data were single entered, double checked into SPSS version 16.00 [SPSS Inc, Chicago, IL, USA]. All records were checked for completeness, reliability and precision.

During the study period, 152 cases received the full three doses of IFN-1-a plus lopinavir and ritonavir and 304 age-and sex-matched as control who received lopinavir and ritonavir alone, were included in the analysis. The median days stayed in hospital was 13 (inter-quartile range [IQR] 5-37) and 6 (IQR 2-28) days among IFN-1-a group and controls group respectively. Table 1 shows demographic and clinical characteristics of both groups. 68% of total patients were male gender and the median age was 56 years (IQR, 44-66). At baseline, patients in control group were more likely to receive invasive ventilation (74 vs. 51, p=0.036) and patients receiving invasive had a tendency to be older (61 years, vs. 54 years, p<0.001), lymphopenia (61% vs. 39%, p= 0.023), more concomitant (73% vs. 47%, p<0.001), including chronic renal failure (6% vs. 1%, p=0.006), hypertension (38% vs. 22%, p<0.001), DM (31% vs. 17%, p= 0.001). There were 57 deaths, including 17 (11%) patients in IFN-1-a group and 40 (13%) patients in control group. The most common symptoms were cough (98%), dyspnea (95%) and fever (91%) followed by headache (47%), myalgia (38%), anosmia (21%), ageusia (20%) and other symptoms ( Table 2 ).

There is no significant difference between IFN-1-a group and control group in mortality rate statistically although IFN-1-a group had less mortality than controls group with considering of oxygen support significantly (p<0.001) ( Table 3 ).

In binary multivariate logistic regression the death rate was 3 times higher in control group besides co-disease and noninvasive ventilation requirement (Table 4 ). After adjusting for age, gender, and DM, noninvasive ventilation requirement (HR 2.80, p=0.001, co-disease (HR 2.30, p=0.021), and regimen without interferon B1a (HR 5.12, p=0.001) remained independently associated with mortality. The cumulative incidence of mortality at 35 days at hospital was higher in control group (Figure 1 ).

The present study shows that the regimen including IFN-1-a and lopinavir plus ritonavir resulted in good prognosis and lower risk of mortality among COVID-19 patients. IFN-1-a can reduce mortality rate at least five times besides noninvasive ventilation and comorbidity. Also, IFN-1-a can improve oxygen support.

Ebola and recently for COVID-19 especially in combination with a nuclease inhibitor (ribavirin) or with a protease inhibitor (lopinavir/ritonavir). They have suggested using this combination in early onset of disease for clinical improving they mentioned association between these medication and their critical situation with mortality. [14, [22] [23] [24] Clementi and colleagues demonstrated in vitro antiviral activity of IFN-1-b on infected cells. Also, they showed that IFN-1-a effectively inhibits virus replication and decreases viral RNA on treated cells. [25] Other studies had various results in the treatment of COVID-19 by interferon type I, including interferon alfa and beta. [26, 27] A multicenter randomized trial compared a triple combination of IFN-1-b, lopinavir/ritonavir, and ribavirin with lopinavir/ ritonavir alone. They reported that the combination therapy was more effective in suppressing the virus shedding, clinical improvement with mild side effects, and duration of hospital stay. [23] In another randomized clinical trial, the efficacy of IFN-1-b was evaluated. IFN-1-b (250 µg every other day for two weeks) was added to lopinavir/ritonavir or atazanavir/ritonavir plus hydroxychloroquine as their national protocol regimen.The control group was on the national protocol regimen. A statistically significant clinical improvement was seen in IFN-1-b group with a remarkable reduction of mechanical ventilation and ICU admission. [28] Most of these studies were focused on the evaluation of IFN-1-b in treatment of COVID-19. We evaluated IFN-1-afor this purpose. We found combination of IFN-1-a and lopinavir/ritonavir is more efficient with considering of oxygen support in survival and discharging the patients with a normal Sao 2 than lopinavir/ritonavir alone.

This result supports other study that it showed SARS-CoV-2 is more susceptible to type I interferon than SARS. [23, 29, 30] There are various results evaluating efficacy of lopinavir/ritonavir alone or in combination with interferon on outcome of treatment. In a recent trial has been shown lopinavir/ritonavir was not efficient in treating COVID-19 that it might be due to late recruitment (median 14 days vs. 7 days). [31] Our study have confirmed this finding of higher rates of all-cause mortalityin control group except that median days at hospital in IFN-1-a group was more than control groups (13 vs. 6 days) .It could be due to disease severity and more comorbidity in IFN-1-a group that it is caused to stay at hospital more than control group. Additionally, the patients should be stayed at hospital for injection of IFN-1-a at least 6 to 10 days.

In present study, all-cause mortality was more common among control group.

Duration of symptoms was not significantly different between two groups, so the higher mortality rate in patients who received IFN-1-a. The high rate of mortality may possibly be related to have comorbidities and to need noninvasive and invasive ventilation in control group. On the other hand, we could not perform autopsies in our center;

consequently, we cannot exclude unrelated death to COVID-19. Besides, this center was a referral center for COVID-19 in pandemic situation.

Major strength of our study is the evaluation of COVID-19 treatment with IFN-1a and comparison to a relevant control group selected at random from the same study base. As many other studies, this report has some limitations. Our center was one of designated hospital for COVID-19, so partly; this finding may not be representative of all setting. Nevertheless, it is more likely that COVID-19 patients treated in other hospitals with less expertise and facilities would have even worse treatment outcomes. Second, we did not consider efficacy of IFN-1-a in suppressing the shedding of SARS-CoV-2 because of the lack of adequate devices for doing PCR. In addition, we did not evaluate other concomitant medications in both groups as a cofounder factor. Finally, we could not perform another nasopharyngeal sample whether we achieved a negative sample as an improvement sign. We discharged the patients if they had Sao 2 more than 93% while breathing ambient air not a negative RT-PCR for SARS-CoV-2.

In summary, this study emphasizes and confirms the similar studies for using interferon beta 1a with lopinavir/ritonavir to achieve best therapy for COVID-19. Severe or critically ill patients who need invasive ventilation or intensive care can be treated with IFN-1-a in combination with other antiviral agents.

None. 

WHO Declares COVID-19 a Pandemic

Covid-19 -Navigating the Uncharted

A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster

E.a.h.w.l.o. Latin American Network of Coronavirus Disease, Clinical, laboratory and imaging features of COVID-19: A systematic review and metaanalysis

Clinical course and mortality risk of severe COVID-19

A pathological report of three COVID-19 cases by minimal invasive autopsies

Severe acute respiratory syndrome coronavirus ORF6 antagonizes STAT1 function by sequestering nuclear import factors on the rough endoplasmic reticulum/Golgi membrane

Interferon responses in viral pneumonias

Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients

Increased sensitivity of SARS-coronavirus to a combination of human type I and type II interferons

SARS: systematic review of treatment effects

Type 1 interferons as a potential treatment against COVID-19

Treatment With Lopinavir/Ritonavir or Interferon-beta1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset

In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds

Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV

COVID-19) Weekly Epidemiological Update and Weekly Operational Update

Factors associated with death or intensive care unit admission due to pandemic 2009 influenza A (H1N1) infection

Euro surveillance : bulletin Europeen sur les maladies transmissibles

NRITLD Protocol for the Management of Patients with COVID-19 Admitted to Hospitals

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the

The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak -an update on the status

Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity

Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an openlabel, randomised, phase 2 trial

Broad-spectrum antivirals for the emerging

Middle East respiratory syndrome coronavirus

Interferon-β-1a Inhibition of Severe Acute Respiratory Syndrome-Coronavirus 2 In Vitro When Administered After Virus Infection

Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings

Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS

Interferon β-1b in treatment of severe COVID-19: A randomized clinical trial

SARS-CoV-2 sensitive to type I interferon pretreatment, bioRxiv

Subcutaneous administration of Interferon beta-1a for COVID-19: A non-controlled prospective trial

A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19